that a systematic collection of data from many African settings might help establish the absolute neutrophil count cutpoints to be used for defining neutropenia in African populations.
There is evidence that African infants have a lower normal range of absolute neutrophil counts (ANC) than white infants. 1, 2 However, this fact remains underappreciated. Indeed, the only available normative tables derive from data in Caucasian populations. 3 When these criteria are applied to African populations, such as might occur in the conduct of an international clinical trial, a substantial degree of misclassification and overestimation of perceived abnormalities might ensue. We present herein our experience during the initial stages of conduct of a clinical trial of an antiretroviral and a nutritional intervention in HIV-infected breastfeeding mothers and their infants in Malawi. In this study, we followed the National Institutes of Health's (NIH's) Division of AIDS (DAIDS) toxicity tables, as is customary during the conduct of large international trials. We found that application of these standards resulted in a great degree of classification of infants as neutropenic, when in fact this may represent values within the normal range for the local population.
Methods
We have recently started enrolling patients into a study of antiretroviral prophylaxis and nutritional interventions among HIV-infected breastfeeding mothers and their infants in Malawi (the Breastfeeding, Antiretrovirals and Nutrition [BAN] study). 1, 2 In this study, HIV-infected mothers and their full-term infants are randomized at birth to an antiretroviral and a nutritional intervention in a 2´3 factorial design. All mothers and infants receive 1 week of twice-daily zidovudine/lamivudine beginning at labor/birth in addition to the standard 2-dose peripartum nevirapine. 4, 5 In addition, mother-infant pairs are randomly assigned at birth to 1 of 3 groups: (1) a group in which zidovudine/lamivudine/nelfinavir is given to the mother for 6 months, (2) a group in which nevirapine is given to the infant for 6 months, or (3) a group receiving no additional prophylaxis. Exclusive breastfeeding for 6 months followed by rapid weaning is also promoted. 6, 7 The mothers and infants are followed clinically and with laboratory evaluations at regular frequent time points.
During the first few months of the study, we noticed that several infants had an absolute neutrophil count (ANC) below the lower limit of normal according to the NIH DAIDS toxicity tables, 3 which are used in the study to grade laboratory results ( Table 1) . White cell counts are determined on a Beckman AcT5 analyzer; recommended quality controls are conducted daily, and low counts are confirmed with manual differentials.
Results
Thus far, 206 infants have been enrolled in the study; longest follow-up has been up to 40 weeks of life. There have been 86 infants with neutropenia at any time point (41.7%), of which 22 were of grade 3 or 4 (10.7%). Twenty-five of the infants had neutropenia at birth (12.1%), of which 9 were of grade 3 or 4 ( Table 2 ). In all instances, the infants' neutropenia resolved or improved by week 40 postpartum without any change in the regimen; correlation between machine and manual differentials has been very good (Pearson's correlation coefficient, r = 0.86). None of the babies with neutropenia developed symptoms of infection. All were thriving infants with no other apparent concurrent conditions and not on other medications except for the study drugs, according to the study arm.
There were no differences between antiretroviral treatment arms or no antiretroviral treatment arm in either neutropenia or grade 3/4 neutropenia (data not shown).
Discussion
The unexpectedly high incidence of neonatal "neutropenia" noted in the study thus far prompted us to reevaluate the suitability of the standards used. A search of the literature indicated that, even though not well appreciated in clinical practice, there are indeed differences in white blood cell counts between black and white individuals. Pediatric textbooks in the United States suggest an ANC cutpoint of <1500/mL for white and <1200/ mL for black individuals to define neutropenia. 1 Reference ranges for ANC vary with age and race; people of African descent have lower ANC counts than whites. 1, 2 Approximately 25% to 50% of persons of African descent have "benign ethnic neutropenia," meaning they have an ANC below the lower limit of "normal" without associated clinical symptomatology or infectious consequences. 2 In the United States, Sadowitz and Oski 8 reported that 10 (20%) of 50 healthy black infants aged 9 to 12 months had an ANC below 1000/mL, whereas none of the white infants had such a low ANC. A recently published study from Uganda demonstrated a lower limit of normal for ANC in infants less than 1 year of age of 900/ mL. 9 Even though a few studies have shown no significant differences in hematologic values between black and white children, 10 most studies, including those based on data from the second National Health and Nutrition Examination Survey (NHANES II), indicate that in all age groups, African American individuals have lower mean white blood cell counts and neutrophil counts than whites. [11] [12] [13] [14] [15] Studies in Africa support this as well. Investigators from Nigeria showed that among 85 healthy African neonates, the lower end of the "normal" ANC range was 980/ mL in the first day of life, 570/mL at week 1, and 650/mL at week 4. 16 Taha and colleagues 17 found that among 2000 healthy infants in Malawi, the fifth percentile of white blood cells (WBC) and the percentage of granulocytes at birth were 4300/mL and 18.1%, respectively; the respective values at 6 weeks of life were 1700/mL and 6.2%. Even though Taha et al did not directly calculate ANC ranges, their results might argue that the normal range for ANC could be less than 1000/mL at birth and even lower at 6 weeks of life. In the HIVNET 023 study, which evaluated the safety and pharmacokinetics of nevirapine given for 6 months to breastfeeding infants born to HIVinfected mothers, the incidence of grade 3 or 4 neutropenia, based on the DAIDS tables, was 22.2% (8/ 36 infants). In all cases, the neutropenia was asymptomatic and resolved promptly without clinical significance (in only 1 case after drug discontinuation). 18 Neutropenia is not a common side effect of nevirapine; indeed, in adults treated with nevirapine, neutropenia was seen in 0.4% to 1.8% of patients in different trials, compared with 0% to 2.8% of patients on placebo. 19 Neutropenia was more commonly seen in children receiving both zidovudine and nevirapine. 19 Up to 56% of infants participating in another ongoing clinical trial in Africa would be determined to have had some grade of "neutropenia" at any given time during their first few weeks of life 20 based on definitions in the DAIDS tables. The proportion of infants in our study that was classified as "neutropenic" is similar to the proportion so classified in these other trials. White blood cell counts in HIV-uninfected infants of HIV-infected mothers, in the absence of their exposure to zidovudine and other antiretroviral agents either in utero or after birth, have not been different from those of infants born to HIV-uninfected mothers, 21, 22 even though studies addressing this question specifically are lacking.
The above evidence suggests that African infants have lower ANC values than Caucasian infants. Even though well documented, this information is not widely known among pediatric investigators in the United States. As a result, DAIDS has issued only 1 set of "standard" toxicity tables, not taking into account racial or ethnic differences. These tables are followed as a guideline when international trials are undertaken. There are no comparable tables from African countries on which to base clinical decisions. The need for such tables is clear. Large studies should be undertaken in different parts of Africa, as genetic heterogeneity exists in different broad geographic locations of the continent. Consideration should be given by the ministries of health or by research foundations/networks to undertake such studies, which might also be useful for other parameters, such as parameters of growth assessment. The high prevalence of HIV in these communities makes this issue more complex; it is unclear presently whether maternal HIV infection might in and of itself affect infant hematologic parameters in the absence of infant infection or prenatal antiretroviral interventions. 15, 17 On the basis of the available evidence, we thus suggest that the ANC cutpoints used to define neutropenia, having been derived from white populations, are not suitable for use in African infants. Such use leads to overdiagnosis of "neutropenia" among African populations and to unnecessary, and possibly harmful, evaluations and changes in drug regimens due to overestimation of toxicity. Until more data are available, we decided and received approval from our ethics boards to adjust the ANC cutpoints used to define neutropenia in infants younger than 56 days by using the same ANC cutpoints used in those older than 56 days (Table 1 ). These proposed modified definitions may still be conservative based on the available information on normal ANC ranges for African infants, which could, in fact, extend below 1200/mL in the first few weeks of life. However, until more data are available, we opted for a more conservative approach to ensure the safety of our study participants. All infants with grade 3 or 4 neutropenia in BAN are monitored closely and evaluated and treated promptly if they develop fever or other signs of infection. Frequent monitoring of ANC is built into the safety laboratory monitoring schedule of our study. Study participants with confirmed, persistent grade 4 neutropenia may be denied further study medications. Using our revised criteria, only 29 of the 206 enrolled infants would have been considered as having neutropenia (14.1%), and only 2 (1%) would have had grade 3 or 4. We suggest that DAIDS should consider modifying the toxicity table for neutropenia in young African infants because the values currently used are not applicable to infants of African descent. Of note, in December 2004, DAIDS did modify the toxicity table for neutropenia (Table 1 ). Using these modified criteria, 54 of the 206 infants enrolled in the BAN study would be classified as neutropenic (26.2%) and 20 as having grade 3 or 4 neutropenia (9.7%). Even though the new criteria represent a step toward addressing the issue of low neutrophil counts in African infants, they are still overly stringent, and a further modification should be considered, using data that become available from the current clinical trials and perhaps other studies specifically designed to provide normative data on hematologic parameters of healthy infants from various parts of Africa.
